Le Centre hospitalier sud francilien est un centre hospitalier regroupant les activités de vingt-sept établissements situés tous en Essonne, dans les villes de Corbeil-Essonnes et de Yerres. Il assure ainsi la couverture hospitalière d'environ 600 000 habitants.

During the past decade, Centre hospitalier Sud Francilien conducted 116 clinical trials. In the 10-year time frame, 116 clinical trials started and 7 clinical trials were completed, i.e. on average, 6% percent of trials that started reached the finish line to date. In the past 5 years, 57 clinical trials started and 3 clinical trials were completed. i.e. 5.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre hospitalier Sud Francilien" #1 sponsor was "Centre Hospitalier Sud Francilien" with 21 trials, followed by "Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète" with 18 trials sponsored, "The Lymphoma Academic Research Organisation" with 13 trials sponsored, "Federation Francophone de Cancerologie Digestive" with 8 trials sponsored and "Groupe Francophone des Myelodysplasies" with 8 trials sponsored. Other sponsors include 102 different institutions and companies that sponsored additional 69 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre hospitalier Sud Francilien" #1 collaborator was "Janssen-Cilag Ltd." with 4 trials as a collaborator, "GERCOR - Multidisciplinary Oncology Cooperative Group" with 3 trials as a collaborator, "UNICANCER" with 3 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 2 trials as a collaborator and "Celgene" with 2 trials as a collaborator. Other collaborators include 79 different institutions and companies that were collaborators in the rest 83 trials.

According to Clinical.Site data, the most researched conditions in "Centre hospitalier Sud Francilien" are "Type 1 Diabetes" (10 trials), "Multiple Myeloma" (7 trials), "Type 2 Diabetes" (5 trials), "Coronary Artery Disease" (4 trials) and "Diabetes" (4 trials). Many other conditions were trialed in "Centre hospitalier Sud Francilien" in a lesser frequency.

Most popular intervention types in "Centre hospitalier Sud Francilien" are "Drug" (81 trials), "Other" (37 trials), "Device" (27 trials), "Procedure" (10 trials) and "Biological" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Lenalidomide" (5 trials), "Rituximab" (4 trials), "Bleomycin" (3 trials) and "Cyclophosphamide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Centre hospitalier Sud Francilien" are 165 trials for "All" genders and 9 trials for "Female" genders.

Currently, there are NaN active trials in "Centre hospitalier Sud Francilien". 1 are not yet recruiting, 29 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 103 completed trials in Centre hospitalier Sud Francilien, 1 suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Centre hospitalier Sud Francilien, 1 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 44 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 42 trials that are defined as “Not Applicable".

Centre hospitalier Sud Francilien has several departments that took part in Clinical trials: "Hematology Dpt, Hôpital Sud Francilien" - 2 trials